Agios Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development of therapies for cancer and rare genetic metabolic disorders. Here's a breakdown of their key activities:
- Research and Development (R&D): Agios is dedicated to discovering and developing investigational medicines that target specific cellular metabolic pathways. This includes the development of therapies for hemolytic anemias, sickle cell disease, and other rare diseases1.
- Clinical Trials: The company has conducted and continues to conduct clinical trials to evaluate the safety and efficacy of its drug candidates. For example, they have completed a Phase 3 study of mitapivat in thalassemia and have announced positive results from this trial2.
- Regulatory Approvals: Agios has had FDA approvals for its drugs, such as mitapivat for the treatment of pyruvate kinase deficiency and ivosidenib for the treatment of IDH1 mutation-positive cancers3.
- Partnerships and Collaborations: The company has entered into partnerships with other pharmaceutical companies to develop and commercialize its drug candidates. For instance, they partnered with Celgene to develop metabolic immuno-oncology therapies4.
- Corporate Social Responsibility: Agios is committed to patient support and community engagement. They have a myAgios patient support services program that provides access support, prescription fulfillment, financial assistance, disease education, and community connections1.
Overall, Agios Pharmaceuticals is focused on leveraging its expertise in cellular metabolism to develop innovative therapies for patients with unmet needs.
8/18/2024 11:09pm
